16. (Amended) An immunogenic composition [for administration to] useful for treating a patient mammal having diseased cells, comprising:

(a) an isolated autologous target diseased cell; and

(b) two or more different bridge molecules each comprising a binding site for a different costimulatory molecule on the surface of T cells, wherein said bridge molecules are attached to the surface of said target diseased cell.

18. (Amended) An immunogenic composition [for administration to] useful for treating a patient mammal having diseased cells, comprising:

(a) an isolated autologous target diseased cell; and

(b) a bridge molecule comprising two or more different binding sites for two or more different costimulatory molecules on the surface of T cells, wherein said bridge molecule is attached to the surface of said target diseased cell.

33. (Amended) A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the step of administering to said patient mammal a pharmaceutically effective amount of an immunogenic composition which comprises:

(a) an isolated autologous target diseased cell which expresses one or more primary and costimulatory T cell activation molecules at a level higher than that in said diseased cells in said patient mammal;

(b) a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal, wherein said bridge molecule is attached to said target diseased cell.

36. (Amended) A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:

(a) providing an isolated autologous target diseased cell;

(b) treating said target diseased cell to increase the levels of one or more primary and costimulatory T cell activation molecules in said target diseased cell;

(c) providing a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal;

(d) attaching said bridge molecule to said target diseased cell; and

(e) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering said collection to said patient mammal;

wherein said steps (c) and (d) are performed either before or after said step (b).

39. (Amended) A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:

(a) providing an isolated autologous target diseased cell;

(b) providing a bridge molecule comprising a binding site for a costimulatory molecule on the surface of T cells in said patient mammal;

(c) attaching said bridge molecule to said target diseased cell;

(d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering said collection to said patient mammal; and

(e) administering a pharmaceutically effective amount of one or more cytokines to said patient mammal to increase the levels of one or more primary and costimulatory T-cell activation molecules in said target diseased cell.

42. (Amended) A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:

(a) providing an isolated autologous target diseased cell;

(b) providing a bridge molecule comprising two or more binding sites for two or more different costimulatory molecules on the surface of T cells in said patient mammal;

(c) attaching said bridge molecule to said target diseased cell; and

(d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering them to said patient mammal.

45. (Amended) A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:

(a) providing an isolated autologous target diseased cell;

(b) providing two bridge molecules each comprising a binding site for a different costimulatory molecule on the surface of T cells in said patient mammal;

(c) attaching said bridge molecules to said target diseased cell; and

(d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecules attached thereto and administering them to said patient mammal.

Applicant believes that no fee is due in connection with this response because the 30 day deadline for responding to the restriction requirement falls on Saturday, February 7,

1998. If any fee is required in relation to this response, please charge our Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON LLP

By _____
Anthony C. Chen
Reg. No. 38,673

ACC:kag
Library Tower
633 West Fifth Street, 47th Floor
Los Angeles, CA 90071-2066
Telephone: (619) 552-8400
Facsimile: (213) 955-0440